Home
Immuno-Oncology
26 September - 27 September 2018
Immuno-Oncology

SAE Media Group inaugural Conference
Immuno-Oncology
26 - 27 September, 2018 | London, UK
-------------------------------------------------------------------------------------------
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies.
This event will draw together different, key facets of the rapidly evolving field to propagate invigorating and thought-provoking discussions between industry leaders and inform and update delegates on current key areas for development, on future potential therapies advancements and provide revisions of regulations.
 

The Immuno-Oncology conference will focus of a few key areas of the field – the promising data coming out from CAR-T Cell Therapy trials and the success of the Immune Checkpoint Inhibitor from MSD. The use of oncolytic viruses in therapeutic vaccines will be explored, along with using bispecific antibodies as targeted therapies. Combination treatments will be discussed, drawing together all the key areas, to look towards the future of Immuno-Oncology and how the field can progress.
To view the full agenda visit the Download Centre

EXCLUSIVE CONTENT - Interview with Grace Macaulay, Global Safety Physician, Patient Safety-Oncology, Medimmune
Read full transcript on the Download Centre
Follow #immunooncologySAE Media Group for Immuno-Oncology event and industry news

FEATURED SPEAKERS

David Giljohann

David Giljohann

CEO, Exicure Inc.
James Legg

James Legg

Vice President R&D, Crescendo Biologics Ltd
Jonathan Wan

Jonathan Wan

MD, PhD Student, Cancer Research UK
Kandeepan Ganeshalingam

Kandeepan Ganeshalingam

Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited

Aman Singh

PK-PD Scientist, Janssen
Aman Singh

Aman received his Master’s in Pharmacometrics from Department of Pharmaceutical Sciences, UB from Dr. Wojciech Krzyzanski’s lab in 2012 working on translational PKPD models for monoclonal antibodies. He joined Dr. Dhaval Shah’s lab in 2013 for his PhD working on different aspects of Antibody-Drug Conjugates (ADCs). He is currently working the Biologics Development Sciences Department of Janssen R&D as PK-PD Scientist.
Besides that he also has industrial experience in different modeling and simulation positions in Pfizer, Cognigen Corporation and Genentech.
 

Andrew Exley

Medical Assessor, MHRA
Andrew 	 Exley

Dr Andrew Exley is a Medical Assessor in the Biologicals and Biotechnology Unit within the Licensing Division of the MHRA in London. He provides bench to bedside expertise in immunology and regulatory affairs including diagnostics, biomarkers, and clinical endpoints, from a background of extensive experience as a consultant immunologist. Medical training includes undergraduate studies at Balliol College, Oxford with a BA Hons Physiological Sciences, and the medical degree from The Royal London Hospital in Whitechapel. Postgraduate studies include the Royal Postgraduate Medical School, Hammersmith Hospital with an MD on TNF and Septic Shock, and the University Hospitals of Birmingham, leading to FRCP and FRCPath Immunology. Dr Exley provides scientific and regulatory advice on cytokines, monoclonal antibodies, novel chimaeric proteins, immunotoxins, synthetic antigen mimics, and ATMPs including gene therapies, CAR T cells, novel cell therapies. Support is provided for national, decentralised and centralised procedures through the assessment of clinical dossiers together with scientific and regulatory advice within accelerated PRIME and EAMS_PIM procedures.
 

Caroline Hull

Research Associate, Kings College London
Caroline Hull

Caroline Hull obtained her PhD from King’s College London in 2015 where she developed cell therapies for autoimmune diseases using lentiviral T cell receptor gene transfer. More recently her research has focused on developing CAR T cell therapies for solid tumours, specifically mesothelioma.

Christopher Perrett

Regulation Manager, Human Tissue Authority
Christopher Perrett

Chris is Regulation Manager at the Human Tissue Authority (HTA) and is part of the Regulation Directorate. He leads inspections in all of the HTA’s sectors (especially the research sector), develops policies for the sectors, is involved in training, and is part of the team developing strong links with stakeholders and other organisations. These include the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Agency (MHRA), the Human Fertilisation and Embryology Authority (HFEA), NHS Blood and Transplant (NHSBT) and the United Kingdom Accreditation Service (UKAS).
Chris is also Guidance Project Manager at the HRA, where he has worked since February 2016. As a member of the Quality, Standards and Information Directorate, he is involved in reviewing the Integrated Research Application System (IRAS) for Research Tissue Banks (RTBs) and research projects. He has also been involved in developing the HRA E-learning package on research involving human tissue.
Chris’s previous background was in research. He holds a degree in Natural Sciences and an MSc and PhD in Molecular Oncology. His previous career was in academia. He was a senior lecturer in oncology at University College London (UCL) and led a research team investigating the causes and treatment of breast and ovarian cancer.
 

David Giljohann

CEO, Exicure Inc.
David Giljohann

Dr. Giljohann has served as CEO of Exicure since 2013. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University under the direction of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and Spherical Nucleic Acid (SNA™) constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications.

Harry Smith

Medical Scientist, Gilead Ltd
Harry Smith

On completion of his degree in biochemistry & biological chemistry, Harry joined the pharmaceutical industry and has over 10 years of experience operating within numerous functions including pharmacovigilance, medical information and medical affairs. Over the past 7 years, he has focussed on Oncology and Haemato-oncology working for some of the leaders in the field; including Roche, Novartis and GlaxoSmithKline. Harry joined Gilead in 2015 as a Medical Scientist covering the South East of the U.K. He has a deep passion for the science behind Oncology and is undertaking an MSc in cancer and therapeutics at the Bart’s Cancer Institute and Queen Mary University of London.

James Legg

Vice President R&D, Crescendo Biologics Ltd
James Legg

James Legg is currently VP Research and Development at Crescendo Biologics in Cambridge UK where he is responsible for Crescendo's building portfolio of Immuno Oncology Humabody Biologics. Prior to joining Crescendo, James completed a Ph.D in Molecular Cell Biology from Imperial College London and a Post Doc at Imperial Cancer Research Fund (now CRUK) before moving into the Biotechnology industry with a role at Cambridge Antibody Technology and then a number of positions within MedImmune, the Biologics arm of AstraZeneca.

Jana Schockaert

Scientist, ImmunXperts
Jana Schockaert

Jana holds a master’s degree in biomedical sciences from the University of Ghent since 2016, with a specialization in the field of immunology by completing a thesis project about Natural Killer cell differentiation. She started her career as Research Associate in the Cell Based Solutions team at Ablynx, where she gained experience in performing various cellular- and flow cytometry-based assays. Afterwards she joined ImmunXperts as Scientist, where she now is dedicated to operating and setting-up various immuno-oncology specific projects.

Jonathan Wan

MD, PhD Student, Cancer Research UK
Jonathan Wan

Jonathan C. M. Wan is an M.B. Ph.D. student at Trinity College, University of Cambridge, UK. He completed his preclinical medical studies at King's College London, UK, and is currently carrying out his Ph.D. in Nitzan Rosenfeld's laboratory at the Cancer Research UK Cambridge Institute, University of Cambridge (2015–18), where he is developing individualised circulating tumour DNA assays to monitor patients with melanoma with high sensitivity.

Kandeepan Ganeshalingam

Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
Kandeepan Ganeshalingam

Kandeepan Ganeshalingam received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.
Following a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the Oncology product development team at Roche in 2007. In this role he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as Senior Medical Director, in immunology and was subsequently promoted to Group Medical Director in Oncology, where he led the Global Medical team responsible for multiple Haematology/Oncology products. In this role he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.
In 2016, he joined Merck Sharp Dohme as Executive Director, Oncology Therapeutic Area Head, European Clinical Development, where he is involved in the clinical development of cancer immunotherapies.
 

Loui Madakamutil

VP, Discovery and Research, Nektar Therapeutics
Loui Madakamutil

Loui Madakamutil is currently VP and Head of Discovery and Research at Nektar Therapeutics and is responsible for the overall discovery strategy of Nektar to deliver novel immuno-modulatory medicines in several therapeutic areas including Cancer and Auto-inflammatory diseases. Previously, Loui was a Senior Director and Lead for Rheumatology-DAS at Janssen Research Division for 2.5 years where Loui was responsible for the discovery strategy and delivering portfolio assets from early ideas to proof of concept in humans in Rheumatic diseases. Loui held appointment as the Site Head of Immunology at Takeda Pharmaceuticals in San Diego and, over a 5 year period, held positions of increasing responsibility in Drug Discovery and Early Development and was responsible for driving Takeda’s Discovery strategy in Immunology with a focus on inflammatory bowel disease (IBD) and Cancer Immunology. Loui also spent five years in Immunology discovery at Celgene in the Experimental Therapeutics Team. He has taken several large and small molecule compounds into Phase 1a. Loui did his Post-Doctoral training at the La Jolla Institute for Allergy and Immunology, first with Eli Sercarz and then with Hilde Cheroutre. Loui has a PhD in applied immunology from the University of Mumbai India and an MS in Biochemistry.

Neil Brewis

Chief Scientific Officer, F star
Neil Brewis

Neil has 20 years’ experience in drug discovery and development and has successfully led a growing portfolio of antibody, antibody fragment and recombinant protein therapeutics from concept to clinical development. He joined F-star from GlaxoSmithKline (GSK) where he was Vice President, Head of Biopharmaceutical Research. Neil played a key leadership role, as Head of Research, in the success of building Domantis until the company was acquired by GSK in 2007. Neil is an Honorary Doctor of Science from Hertfordshire University and sits on the BBSRC Council. He holds a PhD in Biochemistry from Dundee University, UK.

Paul Cockle

Head of Immunology, PsiOxus Therapeutics
Paul Cockle

Dr Paul Cockle is Head of Immunology at PsiOxus Therapeutics Ltd, where he is coordinating the activities of a team of highly skilled scientists engaged in progressing novel immune modulating candidates from the company’s cancer gene therapy T-SIGn oncolytic virus platform and developing innovative approaches for evaluating the activities of new viruses. After obtaining his D.Phil in Clinical Medicine from Oxford University, he pursued a career in tuberculosis vaccine research, before joining Pfizer to help establish their newly formed Vaccine Research group. After initially working on vaccines against infectious disease, he moved into the field of therapeutic vaccines, including that of cancer vaccines. More recently, Dr Cockle joined Gritstone Oncology to help develop their personalized neoantigen-targeted therapies, before making his move to PsiOxus Therapeutics at the start of the year.

Philip Howard

Chief Scientific Officer, Spirogen
Philip Howard

Dr Howard is a Founding Scientist and Chief Scientific Officer at Spirogen. He has been conducting research into the pyrrolobenzodiazepine (PBD) family of antitumor antibiotics for twenty years in both academia and industry. Philip has worked as a part of a multi-disciplinary team, supported by Cancer Research UK and Spirogen, on the synthesis, biological evaluation and development of the PBD dimers. Since 2008 he has been working on the development of the PBDs as payloads for antibody-drug conjugate therapy with a number of leading companies including, Seattle Genetics, Stemcentrx, ADC Therapeutics, Genentech, Regeneron and Tanabe Research Laboratories USA Inc. Dr Howard designed the tesirine payload (SG3249) and the warhead SG3132 released by the talirine payload. His work at MedImmune is focused on the further development of their PBD-ADC platform. At the time of writing, more than 23 PBD-ADCs, arising from Spirogen collaborations, have been submitted to clinicaltrials.gov for 11 targets.

Robert Boyd

Director Discovery, Oxford BioTherapeutics
Robert Boyd

Dr Robert Boyd has over 20 years of experience in antibody target discovery and therapeutic development. He is a scientific director at Oxford BioTherapeutics (OBT, UK) and leads novel therapeutic programs in Immuno oncology. He joined OBT from the MRC Toxicology Unit where he was a senior investigator. He has held senior scientific positions at Oxford GlycoSciences and Speywood Pharmaceuticals focused on targeted medicines. Dr Boyd holds a PhD in Biochemistry from Sussex University, and conducted post-doctoral research at the Royal Postgraduate Medical School and the Imperial Cancer Research Fund.

Rochana Wickramasinghe

Evaluation Director, AstraZeneca
Rochana  Wickramasinghe

Ro joined AstraZeneca in 2015 as an Evaluation Director in the Oncology Business Development team. He is responsible for leading the evaluation of new in-licensing and out-licensing opportunities in late stage oncology as well as Immuno-oncology clinical collaborations. Ro led the divestment of AstraZeneca’s rare disease thyroid cancer therapy Caprelsa to Sanofi/Genzyme for up to $300m. Ro has also led several Immuno-Oncology clinical collaboration deals including with Immunomedics combining IMFINZI (PD-L1 inhibitor) with IMMU-132 in first-line triple negative breast and bladder cancers, Celgene, NewLink Genetics, GSK and ADC Therapeutics.

Ro received his PhD in Oncology from Trinity College, Cambridge on a Gates Scholarship, and has an MBA from the Cambridge Judge Business School.
 

Shahram Lavasani

CEO, ImmuneBiotech AB
Shahram Lavasani

Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He is a skillful immunologist, with many years of teaching and research expertise on gastrointestinal complications in autoimmune and chronic inflammatory diseases. Focusing on Gut-Brain axis he has pioneered research in MS, which is an autoimmune disease of the central nervous system, by demonstrating inflammation and increased permeability in the gut and introduced microbiota-based therapies using combination of probiotic bacteria. He is the founder of ImmuneBiotech, developed a proprietary lactobacilli library and established accurate and multiple selection technologies to screen and design formulations for the optimal therapeutic management of the diseases. ImmuneBiotech´s first product, designed to address the underlying causes of Irritable Bowel Syndrome (IBS), has shown major success and will soon be available in the market.

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

James Legg, Vice President R&D, Crescendo Biologics Ltd

clock

9:10

Combination therapy in Immuno-Oncology

Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited

  • Channelling the immune system to improve long term disease control and survival across a wide range of cancers
  • Innovative combination strategies to improve upon monotherapy activity and overcome resistance
  • Importance of patient selection in cancer immunotherapy
  • clock

    9:50

    Targeting Immune Checkpoints with Humabody VH Therapeutics

    James Legg, Vice President R&D, Crescendo Biologics Ltd

  • Crescendo Biologics’ development of Humabody VH products, small highly adaptable and flexible proteins which can be developed into differentiated therapeutics
  • A description of Crescendo’s approach to developing differentiated Immuno oncology therapeutics with several examples of molecules in our research pipleline.
  • Case studies include a BiParatopic PD-1 inhibitor which shows efficacy in an anti-PD-1 insensitive in vivo model, a BiSpecific molecule inhibiting both PD-1 and LAG3 for overcoming resistance or insensitivity to PD-1 inhibition and a Targeted IO approach in which T-cell co-stimulation is focused away from the periphery and into the tumour microenvironment in order to improve the narrow therapeutic index observed with standard T-cell agonist antibodies.
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-biased cytokine

    Loui Madakamutil, VP, Discovery and Research, Nektar Therapeutics

  •  NKTR-214 biases signalling through the IL-2 receptor pathway to generate profound effector T-cell responses while reducing regulatory T-cell activity in tumours
  • Combination dosing of NKTR-214 dramatically enhances activity of several tumour vaccine modalities in mouse models
  • The unique profile of T-cell activity generated by NKTR-214 may enable the next generation of tumour vaccines
     
  • clock

    11:40

    The use of Bispecific Antibodies to modulate Anti-Tumour immune responses

    Neil Brewis, Chief Scientific Officer, F star

  • Bispecific antibodies: an attractive alternative to cancer treatments combinations
  • F-star’s approach to create bispecific mAb²
  • In vitro and in vivo efficacy of F-star bispecific antibodies targeting oncology pathway
  • clock

    12:20

    The development of therapeutic antibodies to novel IO targets

    Robert Boyd, Director Discovery, Oxford BioTherapeutics

  • Novel IO target discovery
  • Development of therapeutic antibodies to novel IO targets
  • Tumor explant models for IO target validation and testing of IO molecules

  • clock

    13:00

    Networking Lunch

    clock

    14:10

    Application of PK-PD Modeling and Simulation in Development of T-Cell Redirecting Antibodies

    Aman Singh, PK-PD Scientist, Janssen

  • Platform Target-Biologic-Effector Engagement Model
  • Evaluation of key parameters (e.g. Target/T-cell affinity, E:T Ratio) on Cytolysis and T-cell Activation
  • Evolution of the developed platform model to Multi-specific Biologics
  • Preclinical-to-Clinical Translation
  • clock

    14:50

    Unwanted immunogenicity and functionality testing of immuno oncology drugs

    Jana Schockaert, Scientist, ImmunXperts

  • Tools for early unwanted immunogenicity assessment: in silico and in vitro assays
  • In vitro functional testing to accelerate immune oncology drug design
  • Optimal Early lead selection
  • clock

    15:30

    Afternoon Tea

    clock

    16:00

    T4 CAR T cell immunotherapy of patients with refractory head and neck cancer

    Caroline Hull, Research Associate, Kings College London

  • A CAR has been engineered using a promiscuous ligand that engages 8 distinct ErbB dimer species
  • Phase 1 evaluation has been initiated in patients with head and neck cancer, using intra-tumoural delivery and phased dose escalation to mitigate risk
  • Thirteen patients have been safely treated to date, at doses of up to 1Bn cells, without DLTs and with an efficacy signal evident
     
  • clock

    16:40

    Could the microbiome boost cancer immunotherapy?

    Shahram Lavasani, CEO, ImmuneBiotech AB

  • Understanding of the dynamics and function of the human microbiome in health and disease
  • Dysbiosis and Cancer Therapy
  • Microbial interventions
  • clock

    17:20

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    James Legg, Vice President R&D, Crescendo Biologics Ltd

    clock

    9:10

    Developing tumor-specific immunogene (T-SIGn) combination immunotherapies by arming the oncolytic group B adenovirus enadenotucirev

    Paul Cockle, Head of Immunology, PsiOxus Therapeutics

  • Platform: a potent chimeric oncolytic adenovirus enadenotucirev engineered to deliver transgenes selectively to tumors
  • Approach: localized production of a combination of immunotherapeutic agents within tumors following systemic dosing.  Multiple, mechanism-driven product design opportunities – candidate pipeline generated
  • Benefits: optimizing concentrations of agents within the tumor where they need to act, while minimizing the potential for systemic toxicity via off-target effects
     
  • clock

    9:50

    ADC-IO combination treatments

    Philip Howard, Chief Scientific Officer, Spirogen

  • Combining  ADC and IO therapies
  • ADC/IO Case Studies
  • IO/PBD-ADC combinations 
  • Immunomodulatory properties
  • Synergy with immunotherapies

  •  

     

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Innate Immune Activators- Spherical Nucleic Acid TLR9 in Combination with Checkpoint Inhibitors

    David Giljohann, CEO, Exicure Inc.

  • Spherical Nucleic Acids (SNAs) are 3D forms of DNA and RNA that enter cells naturally
  • SNAs can be used to potently activate Toll-like-receptor (TLR) pathways
  • Pre-clincal work has shown activity in Breast, Lung, Melanoma, and Colorectal cancers in combination with checkpoint inhibitors
  • Phase I normal volunteer studies were begun in October 2017, results of which will be shared
  • clock

    11:40

    Human Tissue research in the UK: Ethics and Regulation

    Christopher Perrett, Regulation Manager, Human Tissue Authority

  • Ethical approval and regulation of Human Tissue research
  • The roles of the Health Research Authority (HRA)
  • The roles of the Human Tissue Authority (HTA)

     

  • clock

    12:20

    Networking Lunch

    clock

    13:30

    Generating symbiosis with regulatory affairs in Immuno-Oncology

    Andrew Exley, Medical Assessor, MHRA

  • How are the regulations keeping up with innovation and evolving therapeutic approaches?
  • The differentiation between European vs American procedures of approval
  • Is there likely to be a gap between patients’ therapeutic access, restricted by approval procedures
  • What are the current barriers to entry in the market?
  • clock

    14:10

    Clinical collaborations in IO – why do them and what pharma looks for

    Rochana Wickramasinghe, Evaluation Director, AstraZeneca

  • History of clinical collaborations in IO
  • How IO clinical collaborations have changed the business model for how pharma and biotech interact
  • Why should biotechs enter into an IO clinical collaboration with pharma?
  • What does pharma look for in a biotech when deciding whether or not to enter into a clinical collaboration?


     

  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    The tumour mutation burden and using this as an indication of treatment choice

    Harry Smith, Medical Scientist, Gilead Ltd

  • The effect of a higher number of somatic mutations on the susceptibility to treatment
  • Why a higher somatic mutation rate increases the chance of response to IO treatments
  • How the tumour mutation burden can be harnessed to optimise the effect of therapies
  • The cut off points used and the validation of this point
  • clock

    16:00

    Emerging Applications of Liquid Biopsies in Immuno-Oncology

    Jonathan Wan, MD, PhD Student, Cancer Research UK

  • An introduction to the field of liquid biopsies will be given, and the biology explored
  • Technologies and platforms for circulating tumour DNA (ctDNA) analysis will be outlined and appraised
  • Clinical applications of liquid biopsies in oncology will be explored
  • Recent data on the use of liquid biopsies for monitoring immunotherapy will be discussed
  • clock

    16:40

    Chairman’s Closing Remarks and Close of Day Two


    PK-PD Scientist
    Janssen
    Medical Assessor
    MHRA
    Research Associate
    Kings College London
    Regulation Manager
    Human Tissue Authority
    CEO
    Exicure Inc.
    Medical Scientist
    Gilead Ltd
    Vice President R&D
    Crescendo Biologics Ltd
    Scientist
    ImmunXperts
    MD, PhD Student
    Cancer Research UK
    Executive Director, Therapeutic Area Head Oncology
    Merck Sharp & Dohme Limited
    VP, Discovery and Research
    Nektar Therapeutics
    Chief Scientific Officer
    F star
    Head of Immunology
    PsiOxus Therapeutics
    Chief Scientific Officer
    Spirogen
    Director Discovery
    Oxford BioTherapeutics
    Evaluation Director
    AstraZeneca
    CEO
    ImmuneBiotech AB

    Supporting Media Partners

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Preliminary Attendee List

    Download

    Brochure

    Download

    Interview with Dr Andrew Exley - MHRA

    Download

    Latest Agenda

    Download

    University of Antwerp 2017 Presentation

    Download

    Hôpital Européen Georges Pompidou 2017 Presentation

    Download

    INSERM 2017 Event Presentation

    Download

    Chairman Dr James Legg's Letter

    Download

    [Attendee list]

    Download

    [Speaker Line-up]

    Download

    Media Partners


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Pharmalicensing

    Supporting Media Partners
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc


    Contract Biotechnology

    Supporting Media Partners
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    American Pharmaceutical Review

    Supporting Media Partners
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Immune Regulation News

    Supporting Media Partners
    https://www.immuneregulationnews.com/?utm_source=immunooncol2018&utm_medium=banner&utm_campaign=irnimmunooncol2018

    Immune Regulation News is a free, weekly e-newsletter that keeps members of the immune regulation community informed by providing the latest news from all areas of the field, including science, research and business, to regulatory affairs. Subscribe now to stay current in the latest research news.


    World Pharma News

    Supporting Media Partners
    http://www.worldpharmanews.com/



    Biocompare

    Supporting Media Partners
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Target Review

    Supporting Media Partners
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Gate2Biotech

    Supporting Media Partners
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharmaceutical Technology

    Supporting Media Partners
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporting Media Partners
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    Antibodies

    Supporting Media Partners
    http://www.mdpi.com/journal/antibodies

    /Antibodies/ (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens, especially how to quickly translate basic research results to therapeutic applications. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Antibodies is covered by Emerging Sources Citation Index (ESCI) and DOAJ.


    Labiotech.eu

    Supporting Media Partners
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Pharmacircle

    Supporting Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Swiss Biotech Association

    Supporting Media Partners
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Oncology Central

    Supporting Media Partners
    http://www.oncology-central.com

    Oncology Central is the online knowledge hub open to all healthcare professionals, offering access to breaking news, peer-reviewed articles and exclusive content to members of the oncology community.


    Drug Development Technology

    Supporting Media Partners
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Human Immunology News

    Supporting Media Partners
    https://www.humanimmunologynews.com/?utm_source=immunooncol2018&utm_medium=banner&utm_campaign=hinimmunooncol2018

    Human Immunology News is a free, weekly e-newsletter that keeps members of the human immunology community informed by providing the latest news from all areas of the field, including science, research and business, to regulatory affairs. Subscribe now to stay current in the latest research news.


    SciDoc Publishers

    Supporting Media Partners
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    BioPartner UK

    Supporting Media Partners
    http://biopartner.co.uk/index.php

    BioPartner UK is the accredited trade organisation that provides practical support and international promotion to UK Life Sciences companies, who wish to grow their business overseas. BioPartner signposts to UK expertise and leads delegations to promote the UK presence at major international biopharma conferences. By operating in partnership with the UK government and event organisers, BioPartner assists all UK companies with access to government grants and heavily discounted entry fees. Members of the BioPartner Programme receive extra benefits and support to effectively trade overseas.


    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmaceutical Outsourcing

    Supporting Media Partners
    http://www.pharmoutsourcing.com

    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


    American Laboratory

    Supporting Media Partners
    http://www.americanlaboratory.com

    For laboratory managers and researchers utilizing analytical chemistry and its applications, seeking knowledge on new technologies, methods, applications, and products, the American Laboratory® publication platform provides comprehensive technology coverage for laboratory professionals at all stages of their careers. Unlike single-channel publications, American Laboratory® is a multidisciplinary resource that engages scientists through print, digital, mobile, multimedia, and social channels to provide practical information and solutions for cutting-edge results. American Laboratory® serves the need of global community of laboratory professionals for communicating relevant technical advances and insights. Globally, American Laboratory® reaches out to subscribers by offering digital distribution plus premium print in North America. Digital communications utilize internet, mobile and social channels.


    BioIndustry Association

    Supporting Media Partners
    https://www.bioindustry.org/

    The BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.


    European BioPharmaceutical Review (EBR)

    Supporting Media Partners
    http://www.samedanltd.com

    European BioPharmaceutical Review (EBR) provides a dedicated platform of communication and information for the biopharmaceutical market across Europe, North America and the rest of the world. Each quarterly issue, 10,500 copies of the magazine are distributed to our specially-targeted readership with articles on the hottest topics written by eminent commentators from the biotech scene.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.